Grant: Idea to Innovation
University of Toronto
$123,950.00
Device for cell separation based on manipulation of settling velocity
EF 2012-13
Résumé
There are currently no label-free separation techniques suitable for isolation of cardiomyocytes (CMs) at high purity and sufficient yield for use in drug discovery or tissue engineering. Since postnatal CMs are terminally differentiated they cannot be expanded from primary sources such as heart biopsies. Advances in stem cell biology have enabled generation of millions of human CMs from pluripotent stem cells. However, engineering advances are required to develop new methods for isolation of live cells label-free. As the majority of known CM markers are intracellular proteins, antibody staining or genetic labeling have been the main techniques used for identification and separation of CMs. The nature of the labeling for intracellular markers is destructive to the cell. Genetic labeling of cells for clinical applications cannot be performed in humans due to ethical concerns. Commercial scale antibody-based separation can also be cost prohibitive. We have developed and proved a completely new approach: using microfluidic devices for label-free separation of CMs, based on the manipulation of their settling velocity and relying on their induced paramagnetic properties. The basis for the separation is the high amount of iron in CMs found in myoglobin when compared to other cardiovascular cells. In this approach, the magnetic field and the field gradient drive the separation of the cells. Upon application of the magnetic field, paramagnetic CMs remained in the vertical column while fibroblasts and other non-myocytes traveled out of the column, enabling enrichment to 94-96% of the fixed adult rat CMs. In this proposal we will validate the device with human CMs, develop a second generation device for improved throughput and build a commercial prototype. Our preferred model is licensing; two potential partners are already identified. The markets for this device include: 1) research tools; 2) supply of pure and live CMs to pharmaceutical companies for drug testing and 3) cell therapy pending appropriate approval. Other uses of this device could be: isolation of skeletal myoblasts, smooth muscle cells and rare cells with weakly expressing surface markers.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
430455-2012
Name nom
Radisic, Milica
Department département
Biomaterials and Biomedical Engineering, Inst. of (IBBME)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
123950
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
Device for cell separation based on manipulation of settling velocity
Keyword
NSERC
Application summary
There are currently no label-free separation techniques suitable for isolation of cardiomyocytes (CMs) at high purity and sufficient yield for use in drug discovery or tissue engineering. Since postnatal CMs are terminally differentiated they cannot be expanded from primary sources such as heart biopsies. Advances in stem cell biology have enabled generation of millions of human CMs from pluripotent stem cells. However, engineering advances are required to develop new methods for isolation of live cells label-free. As the majority of known CM markers are intracellular proteins, antibody staining or genetic labeling have been the main techniques used for identification and separation of CMs. The nature of the labeling for intracellular markers is destructive to the cell. Genetic labeling of cells for clinical applications cannot be performed in humans due to ethical concerns. Commercial scale antibody-based separation can also be cost prohibitive. We have developed and proved a completely new approach: using microfluidic devices for label-free separation of CMs, based on the manipulation of their settling velocity and relying on their induced paramagnetic properties. The basis for the separation is the high amount of iron in CMs found in myoglobin when compared to other cardiovascular cells. In this approach, the magnetic field and the field gradient drive the separation of the cells. Upon application of the magnetic field, paramagnetic CMs remained in the vertical column while fibroblasts and other non-myocytes traveled out of the column, enabling enrichment to 94-96% of the fixed adult rat CMs. In this proposal we will validate the device with human CMs, develop a second generation device for improved throughput and build a commercial prototype. Our preferred model is licensing; two potential partners are already identified. The markets for this device include: 1) research tools; 2) supply of pure and live CMs to pharmaceutical companies for drug testing and 3) cell therapy pending appropriate approval. Other uses of this device could be: isolation of skeletal myoblasts, smooth muscle cells and rare cells with weakly expressing surface markers.